Crinetics Pharmaceuticals

Q2 FY2026 EarningsQ2 FY2026 results significantly exceeded consensus expectations across the top and bottom lines. Total revenue reached $25.1M vs. the $14.9M expected, driven by the rapid commercial adoption of PALSONIFY which generated $24.0M in net product revenue. GAAP EPS was -$1.14, beating the consensus mean of -$1.21. On July 6, 2026, the company entered into a definitive agreement to be acquired by Vertex Pharmaceuticals for approximately $10.0 billion, leading to the withdrawal of all future guidance.